About: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 17 September 2007

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2007 (uk) article scientifique publié en 2007 (fr) scientific article published on 17 September 2007 (en) artículu científicu espublizáu en setiembre de 2007 (ast)
publication date	wds:Q81311015-B0058F56-2015-472D-B6FD-3BFFBDC1B1D1
publication date	2007-09-17 00:00:00Z (xsd:dateTime)
author name string	wds:Q81311015-243042AB-B470-48A0-9EA3-D59D75DA9737 wds:Q81311015-28F3DA5C-CEEE-4176-8CBD-6C64F53E2496 wds:Q81311015-327D8A08-E1D2-4616-A8D3-DD1769825684 wds:Q81311015-45ABF305-9166-43C7-B148-33355ADFEAF4 wds:Q81311015-47A7B9DF-DA05-497F-AECD-404E5AFB4124 wds:Q81311015-530FAC87-00EA-4111-8E90-ADD699B94023 wds:Q81311015-7C217A6E-5F10-47BE-AF47-5C3E2C801B14 wds:Q81311015-A2A71155-3564-4357-B548-A37FA67A4325 wds:Q81311015-A7540753-5FEA-4A92-9C86-C8564C8F85D1 wds:Q81311015-D3581656-6121-4C13-9A1E-16FCD631D2EC
author name string	Mithat Gonen Helen X Chen Howard S Hochster Paulo M Hoff Hedy L Kindler Nancy E Kemeny Scott Wadler Ellen M Hollywood Marcus Quinones Meroe Morse
rdfs:label	Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study (en) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study (nl)
skos:prefLabel	Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study (en) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study (nl)
name	Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study (en) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study (nl)
author	wds:Q81311015-B0C41C43-1EF1-4CC7-A014-C555D28416EA wds:Q81311015-C268CFFC-7F23-4D78-AE02-C97996015392
author	Leonard B. Saltz Heinz-Josef Lenz
title	wds:Q81311015-11950C2B-6767-4FAC-85E0-3749E8E0F906
title	Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study (en)
page(s)	wds:Q81311015-93BB9151-2627-45D8-8E1F-B31F105A309F
page(s)	4557-4561
instance of	wds:Q81311015-0A082E07-1F00-4117-9DEC-FE3A02F12149
instance of	scholarly article
main subject	wds:Q81311015-35A2DF24-1345-457F-B4B4-2386A85AA1A2 wds:Q81311015-3A1DA34A-CC5A-4B1D-83C9-11E8264FE0D5 wds:Q81311015-77753DBB-F944-4798-983E-0C06477ED6BA wds:Q81311015-8B45465F-AB64-4A35-8369-402D84E183C1 wds:Q81311015-EAB0BA19-F72C-4EAF-9C52-FD8FFD797844 wds:Q81311015-F0120AB3-5EAE-44B9-B750-88AD9AA5050A
main subject	irinotecan bevacizumab cetuximab colorectal cancer colorectal carcinoma phase II clinical trial
PubMed ID	wds:Q81311015-9170EE00-80DA-4E7F-A90E-0D4DC0D1D153
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17876013
PubMed ID	17876013
published in	wds:Q81311015-0CE408AA-D3F8-4F44-94C7-90B9971D0B91
published in	Journal of Clinical Oncology
issue	wds:Q81311015-5DB41E27-A62C-4B9C-8D82-54F209912B2A
volume	wds:Q81311015-AF3C3408-12DC-40D7-B842-A517976A0712
issue	29
volume	25
DOI	wds:Q81311015-BE783F2E-FA5B-4FD8-9E59-015BA2F55D93
DOI	http://dx.doi.org/10.1200/JCO.2007.12.0949
DOI	10.1200/JCO.2007.12.0949
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q81311015
is cites work of	Modes of resistance to anti-angiogenic therapy Molecular targeted agents for gastric and gastroesophageal junction cancer Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer Integrating anti-EGFR therapies in metastatic colorectal cancer Colorectal cancer Systemic treatment of colorectal cancer Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer Finding the tumor copycat. Therapy fails, patients don't The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Personalized colon cancer care in 2010. Understanding resistance to EGFR inhibitors-impact on future treatment strategies Mechanisms of resistance to HER family targeting antibodies Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways Bevacizumab: a review of its use in metastatic colorectal cancer Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer Aflibercept in the treatment of metastatic colorectal cancer Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer Management of advanced colorectal cancer, Part 2. Safety and feasibility of targeted agent combinations in solid tumours A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009) Treatment in advanced colorectal cancer: what, when and how? Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software